West Pharmaceutical Services, Inc. (WST)
| Market Cap | 24.99B +57.4% |
| Revenue (ttm) | 3.22B +11.2% |
| Net Income | 542.70M +16.2% |
| EPS | 7.48 +17.4% |
| Shares Out | 70.65M |
| PE Ratio | 47.27 |
| Forward PE | 40.59 |
| Dividend | $0.88 (0.25%) |
| Ex-Dividend Date | Apr 29, 2026 |
| Volume | 446,114 |
| Open | 357.92 |
| Previous Close | 357.66 |
| Day's Range | 352.70 - 357.99 |
| 52-Week Range | 206.80 - 367.66 |
| Beta | 1.16 |
| Analysts | Strong Buy |
| Price Target | 365.93 (+3.46%) |
| Earnings Date | Jul 23, 2026 |
About WST
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhanc... [Read more]
Financial Performance
In 2025, WST's revenue was $3.07 billion, an increase of 6.25% compared to the previous year's $2.89 billion. Earnings were $493.70 million, an increase of 0.20%.
Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for WST stock is "Strong Buy." The 12-month stock price target is $365.93, which is an increase of 3.46% from the latest price.
News
West Pharmaceutical price target raised to $365 from $325 at Morgan Stanley
Morgan Stanley raised the firm’s price target on West Pharmaceutical (WST) to $365 from $325 and keeps an Equal Weight rating on the shares. The firm is updating its model…
West to Host Second-Quarter 2026 Conference Call
EXTON, Pa., July 7, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will releas...
West Pharmaceutical price target raised to $410 from $390 at Evercore ISI
Evercore ISI analyst Daniel Markowitz raised the firm’s price target on West Pharmaceutical (WST) to $410 from $390 and keeps an Outperform rating on the shares. The firm’s Q2 preview…
West Pharmaceutical price target raised to $390 from $350 at KeyBanc
KeyBanc raised the firm’s price target on West Pharmaceutical (WST) to $390 from $350 and keeps an Overweight rating on the shares. The firm cites increased confidence in West Pharmaceutical…
West Completes Sale and Transfer of the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System
EXTON, Pa., July 1, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced the company complet...
Barclays upgrades West Pharmaceutical on ‘material’ upside to estimates
Barclays analyst Luke Sergott upgraded West Pharmaceutical (WST) to Overweight from Equal Weight with a price target of $400, up from $310. The firm says it overestimated the risk from…
West Pharmaceutical upgraded to Overweight from Equal Weight at Barclays
Barclays upgraded West Pharmaceutical (WST) to Overweight from Equal Weight with a $400 price target
West Pharmaceutical Services Transcript: 46th Annual William Blair Growth Stock Conference
Strong growth in high-value injectable medicine components, driven by biologics, GLP-1s, and regulatory changes, is fueling double-digit margin and EPS expansion. Leadership transition to a new CEO aligns with strategic growth, supported by robust cash flow and global market presence.
West Pharmaceutical Services Slides: 46th Annual William Blair Growth Stock Conference
West Pharmaceutical Services has posted slides in relation to its latest quarterly earnings report, which was published on June 2, 2026.
West Pharma names former Thermo Fisher executive Lagarde as CEO
West Pharmaceutical said on Monday it appointed former Thermo Fisher Scientific executive Michel Lagarde as its top boss, effective August 31, succeeding longtime chief Eric Green.
West Pharmaceutical says Michel Lagarde to succeed Eric Green as CEO
West Pharmaceutical (WST) Services announced that its Board of Directors has appointed Michel Lagarde to be President and CEO and a member of the company’s Board of Directors starting August…
West Pharmaceutical assumed with Outperform at Wolfe Research
As previously reported, Wolfe Research analyst Mike Polark upgraded West Pharmaceutical (WST) to Outperform from Peer Perform with a $375 price target Q1 was “juicy good,” driven by continued GLP1…
West Appoints Michel Lagarde to be President and Chief Executive Officer
Experienced healthcare and life sciences executive to lead the Company's next phase of growth and innovation EXTON, Pa., June 1, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a ...
West Pharmaceutical assumed at Outperform from Peer Perform at Wolfe Research
Wolfe Research upgraded West Pharmaceutical (WST) to Outperform from Peer Perform as the analyst assumed coverage of the stock.
West Pharmaceutical price target raised to $325 from $315 at Morgan Stanley
Morgan Stanley raised the firm’s price target on West Pharmaceutical (WST) to $325 from $315 and keeps an Equal Weight rating on the shares after having hosted members of West’s…
West Pharma says fully operational after cyberattack, sees no hit to 2026 forecast
West Pharmaceutical Services said on Wednesday it has restored operations across its sites after a cybersecurity attack earlier this month and expects the incident to have no material impact on its ...
West Pharma says operations recovering after cyberattack
West Pharmaceutical Services said on Friday its operations were steadily recovering after a cyberattack earlier this month disrupted manufacturing and logistics globally.
West Pharmaceutical reports ‘significant progress’ in post-cyberattack recovery
West Pharmaceutical (WST) provided a cyberattack update, saying the company continues to make significant progress in restoring its operations globally. Regarding the proprietary products segment, Wes...
West Pharmaceutical Services Transcript: Bank of America Global Healthcare Conference 2026
A recent cybersecurity breach was contained with minimal disruption, and operations are being restored methodically. Strong Q1 results were driven by robust demand for HVP components, GLP-1s, and regulatory changes, supporting raised guidance and long-term growth expectations.
West Pharmaceutical Services Transcript: AGM 2026
The meeting covered board elections, executive compensation, auditor ratification, and a shareholder proposal for an independent board chair, which was not approved. All director nominees were reelected and executive pay was endorsed by a majority.
West to Participate in Upcoming Investor Conferences
EXTON, Pa., April 28, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will pres...
West Pharmaceutical price target raised to $315 from $285 at Morgan Stanley
Morgan Stanley raised the firm’s price target on West Pharmaceutical (WST) to $315 from $285 and keeps an Equal Weight rating on the shares.
West Pharmaceutical price target raised to $310 from $275 at Barclays
Barclays raised the firm’s price target on West Pharmaceutical (WST) to $310 from $275 and keeps an Equal Weight rating on the shares. The firm updated the company’s model following…
West Pharmaceutical price target raised to $400 from $375 at Citi
Citi raised the firm’s price target on West Pharmaceutical (WST) to $400 from $375 and keeps a Buy rating on the shares.
West Pharmaceutical price target raised to $390 from $320 at Evercore ISI
Evercore ISI raised the firm’s price target on West Pharmaceutical (WST) to $390 from $320 and keeps an Outperform rating on the shares.